UroGen begins subject dosing in Phase III bladder cancer drug trial [Yahoo! Finance]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Yahoo! Finance
clinical trial of its investigational drug UGN-103 (mitomycin) for an intravesical solution to treat low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial aims to enrol 87 subjects and will assess the efficacy and safety of the potential treatment. In the single-arm, multicentre trial, each participant will receive a 75mg dose of UGN-103 through intravesical instillation once a week for six weeks. The drug's efficacy will be assessed based on the complete response rate at the three-month visit post-treatment. Patients who achieve a complete response, defined as having no detectable disease in the bladder at the three-month visit, will proceed to the follow-up period of the trial. These patients will be evaluated every three months to monitor their response. They will continue in the study until the occurrence of disease recurrence, progression, death, or until the last patient completes 12 months of follow-up. UGN-103 is a new formulation
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target [Yahoo! Finance]Yahoo! Finance
- UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025Business Wire
- UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation ConferenceBusiness Wire
URGN
Earnings
- 11/6/24 - Beat
URGN
Sec Filings
- 11/18/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- URGN's page on the SEC website